4.6 Article

Mutations in Specific Structural Regions of Immunoglobulin Light Chains Are Associated with Free Light Chain Levels in Patients with AL Amyloidosis

期刊

PLOS ONE
卷 4, 期 4, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0005169

关键词

-

资金

  1. NCI NIH HHS [CA111345, P01 CA062242, R01 CA111345, CA062242] Funding Source: Medline
  2. NIGMS NIH HHS [R01 GM071514, GM071514] Funding Source: Medline

向作者/读者索取更多资源

Background: The amyloidoses are protein misfolding diseases characterized by the deposition of amyloid that leads to cell death and tissue degeneration. In immunoglobulin light chain amyloidosis (AL), each patient has a unique monoclonal immunoglobulin light chain (LC) that forms amyloid deposits. Somatic mutations in AL LCs make these proteins less thermodynamically stable than their non-amyloidogenic counterparts, leading to misfolding and ultimately the formation of amyloid fibrils. We hypothesize that location rather than number of non-conservative mutations determines the amyloidogenicity of light chains. Methodology/Principal Findings: We performed sequence alignments on the variable domain of 50 kappa and 91 lambda AL light chains and calculated the number of non-conservative mutations over total number of patients for each secondary structure element in order to identify regions that accumulate non-conservative mutations. Among patients with AL, the levels of circulating immunoglobulin free light chain varies greatly, but even patients with very low levels can have very advanced amyloid deposition. Conclusions: Our results show that in specific secondary structure elements, there are significant differences in the number of non-conservative mutations between normal and AL sequences. AL sequences from patients with different levels of secreted light chain have distinct differences in the location of non-conservative mutations, suggesting that for patients with very low levels of light chains and advanced amyloid deposition, the location of non-conservative mutations rather than the amount of free light chain in circulation may determine the amyloidogenic propensity of light chains.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Urology & Nephrology

Membranous Nephropathy With Extensive Tubular Basement Membrane Deposits Following Allogeneic Hematopoietic Cell Transplant: A Report of 5 Cases

Samih H. Nasr, Nelson Leung, Samar M. Said, Hassan B. Alkhateeb, Benjamin J. Madden, M. Cristine Charlesworth, Laurence H. Beck, Christopher P. Larsen, Sanjeev Sethi

Summary: Tubular basement membrane (TBM) deposits are rare in non-lupus membranous nephropathy, but have been observed in patients following allogeneic hematopoietic cell transplant. This distinctive clinicopathologic lesion is associated with chronic graft-versus-host disease (cGVHD) and is characterized by global subepithelial and extensive TBM immune complex deposits, along with acute tubular injury and tubulointerstitial inflammation. Treatment with prednisone and/or rituximab has shown to provide partial or complete remission.

AMERICAN JOURNAL OF KIDNEY DISEASES (2022)

Article Medicine, Research & Experimental

Propsective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function

Jason N. Barreto, Joel M. Reid, Carrie A. Thompson, Kristin C. Mara, Andrew D. Rule, Kianoush B. Kashani, Nelson Leung, Thomas R. Larson, Renee M. McGovern, Thomas E. Witzig, Erin F. Barreto

Summary: This study evaluated the pharmacokinetics of high-dose methotrexate (HDMTX) in adult lymphoma patients, finding that the cystatin C-based eGFR equation best predicted MTX clearance and highlighting the high interpatient variability in HDMTX pharmacokinetics.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)

Article Oncology

Mortality trends in multiple myeloma after the introduction of novel therapies in the United States

Moritz Binder, Bharat Nandakumar, S. Vincent Rajkumar, Prashant Kapoor, Francis K. Buadi, David Dingli, Martha Q. Lacy, Morie A. Gertz, Suzanne R. Hayman, Nelson Leung, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Eli Muchtar, Rahma Warsame, Taxiarchis Kourelis, Wilson Gonsalves, Stephen Russell, Yi Lin, Mustaqeem Siddiqui, Robert A. Kyle, Angela Dispenzieri, Shaji K. Kumar

Summary: Recent advancements in disease biology, drug development, and supportive care have led to improved outcomes in multiple myeloma patients. However, disparities exist in mortality trends among patient populations, with older patients and those with unfavorable disease characteristics experiencing higher excess mortality. Efforts should be made to develop safe and effective therapies for these vulnerable patients and to ensure timely access to specialized care in the community.

LEUKEMIA (2022)

Article Hematology

Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma

Joselle Cook, Kah-Whye Peng, Thomas E. Witzig, Stephen M. Broski, Jose C. Villasboas, Jonas Paludo, Mrinal Patnaik, Vincent Rajkumar, Angela Dispenzieri, Nelson Leung, Francis Buadi, Nora Bennani, Stephen M. Ansell, Lianwen Zhang, Nandakumar Packiriswamy, Baskar Balakrishnan, Bethany Brunton, Marissa Giers, Brenda Ginos, Amylou C. Dueck, Susan Geyer, Morie A. Gertz, Rahma Warsame, Ronald S. Go, Suzanne R. Hayman, David Dingli, Shaji Kumar, Leif Bergsagel, Javier L. Munoz, Wilson Gonsalves, Taxiarchis Kourelis, Eli Muchtar, Prashant Kapoor, Robert A. Kyle, Yi Lin, Mustaqeem Siddiqui, Amie Fonder, Miriam Hobbs, Lisa Hwa, Shruthi Naik, Stephen J. Russell, Martha Q. Lacy

Summary: This study investigated the safety and efficacy of intravenous oncolytic virotherapy in patients with relapsed/refractory hematologic malignancies. The results showed that VSV-IFN beta-NIS had significant therapeutic effects in patients with TCL, possibly through a combination of oncolytic tumor destruction and immune response.

BLOOD ADVANCES (2022)

Article Oncology

Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy

Samer K. Khaled, Kathleen Claes, Yeow Tee Goh, Yok Lam Kwong, Nelson Leung, Wlodzimierz Mendrek, Ryotaro Nakamura, Jameela Sathar, Edmund Ng, Narinder Nangia, Steve Whitaker, Alessandro Rambaldi

Summary: This study evaluated the safety and efficacy of Narsoplimab in adults with HSCT-TMA, and the results showed significant improvements in laboratory TMA markers, clinical response, and overall survival.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Urology & Nephrology

Hematopoietic Stem Cell Transplant-M embranous Nephropathy Is Associated with Protocadherin FAT1

Sanjeev Sethi, Benjamin Madden, Marta Casal Moura, Samih H. Nasr, Nattawat Klomjit, LouAnn Gross, Vivian Negron, M. Cristine Charlesworth, Mariam P. Alexander, Nelson Leung, Ulrich Specks, Fernando C. Fervenza, Mark Haas

Summary: In this study, a novel antigen associated with membranous nephropathy (MN) in patients receiving hematopoietic stem cell transplant (HSCT) was identified using laser microdissection and tandem mass spectrometry (MS/MS). The antigen, called FAT1, was detected in the glomeruli of patients with PLA2R-negative MN. Further studies confirmed the presence of FAT1-associated MN in a majority of HSCT-related MN cases. This study provides valuable insights into the pathogenesis of MN in HSCT patients and may contribute to the development of targeted therapies.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

Letter Urology & Nephrology

Pamidronate versus zoledronic acid for the treatment of multiple myeloma-related hypercalcemia reply

Frank Bridoux, Nelson Leung, Jean Paul Fermand

KIDNEY INTERNATIONAL (2022)

Article Hematology

Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation

Aldo A. Acosta-Medina, Ann M. Moyer, Ronald S. Go, Maria Alice V. Willrich, Fernando C. Fervenza, Nelson Leung, Christianne Bourlon, Jeffrey L. Winters, Grant M. Spears, Sandra C. Bryant, Meera Sridharan

Summary: Eculizumab is effective for complement-mediated thrombotic microangiopathy. Discontinuation of therapy does not universally lead to relapse. This study aimed to assess the role of complement genetic variants in predicting recurrence after Eculizumab withdrawal. A total of 280 patients were included, with CFH and MCP/CD46 being the most commonly identified genetic variants. The relapse rate after discontinuation was 29.6%, with CFH and MCP/CD46 variants in canonical splice regions having the highest relapse rates.

BLOOD ADVANCES (2023)

Letter Urology & Nephrology

A Prospective Evaluation of Novel Renal Biomarkers in Patients With Lymphoma Receiving High-Dose Methotrexate

Jason N. Barreto, Kianoush B. Kashani, Kristin C. Mara, Andrew D. Rule, John C. Lieske, Callen D. Giesen, Carrie A. Thompson, Nelson Leung, Thomas E. Witzig, Erin F. Barreto

KIDNEY INTERNATIONAL REPORTS (2022)

Article Urology & Nephrology

Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors

Naba Farooqui, Mark Zaidi, Lisa Vaughan, Trevor D. McKee, Eram Ahsan, Kevin D. Pavelko, Jose C. Villasboas, Svetomir Markovic, Timucin Taner, Nelson Leung, Haidong Dong, Mariam P. Alexander, Sandra M. Herrmann

Summary: This study found that immune checkpoint inhibitors (ICIs) therapy may lead to acute kidney injury (AKI) and there are no biomarkers currently available to distinguish AKI caused by ICIs from other causes. The urine levels of cytokines such as TNF-a, IL-2, and IL-10 were significantly higher in AKI-ICI patients. Therefore, these T-cell responses and their respective cytokines may be helpful in differentiating AKI-ICI from AKI-other.

KIDNEY INTERNATIONAL REPORTS (2023)

Letter Hematology

Spectrum of renal pathological findings in patients with chronic myelomonocytic leukemia and kidney injury

Nate Gipe, Nelson Leung, Terra Lasho, Abhishek Mangaonkar, Hassan Alkhateeb, Aref Al-Kali, Naseema Gangat, William Hogan, Kristen McCullough, Ayalew Tefferi, Mariam Priya Alexander, Mrinal M. Patnaik

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Oncology

Multiple myeloma with acute light chain cast nephropathy

Nelson Leung, S. Vincent Rajkumar

Summary: Light chain cast nephropathy (LCCN) is a significant cause of acute kidney injury (AKI) in patients with multiple myeloma (MM) and is now considered as a defining event of myeloma. While long-term prognosis has improved, short-term mortality remains higher in patients with LCCN if renal failure is not reversed. Rapid reduction of involved serum free light chain is critical for renal function recovery. Treatment algorithm for MM patients with biopsy-proven LCCN or ruling out other causes of AKI is provided based on randomized trial data whenever available. Clinical trial enrollment is recommended prior to following the treatment algorithm.

BLOOD CANCER JOURNAL (2023)

Review Immunology

Glomerulonephritis: immunopathogenesis and immunotherapy

Hans-Joachim Anders, A. Richard Kitching, Nelson Leung, Paola Romagnani

Summary: 'Glomerulonephritis' (GN) refers to a group of immune-mediated disorders characterized by inflammation of the kidney's filtration units. Current classification is based on histopathological lesion patterns, but these patterns do not align well with the diverse pathological mechanisms and do not guide optimal therapy. Instead, a proposed immunopathogenesis-based classification groups GN disorders into five categories, allowing for more targeted and effective treatments.

NATURE REVIEWS IMMUNOLOGY (2023)

Article Urology & Nephrology

Tissue Inhibitor Metalloproteinase-2 and Insulin-Like Growth Factor Binding Protein-7 Kinetics Following Exposure to High-Dose Methotrexate

Jason N. Barreto, Erin F. Barreto, Kristin C. Mara, Andrew D. Rule, John C. Lieske, Callen D. Giesen, Carrie A. Thompson, Nelson Leung, Thomas E. Witzig, Kianoush B. Kashani

KIDNEY360 (2023)

暂无数据